IM Therapeutics is building an HLA-directed platform for new therapies for autoimmune diseases
Location: United States, Massachusetts, Woburn
Employees: 1-10
Total raised: $10M
Founded date: 2015
Investors 1
| Date | Name | Website |
| - | T1D Fund | t1dfund.or... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 15.10.2019 | Series A | $10M | - |
Mentions in press and media 5
| Date | Title | Description |
| 15.10.2019 | IM Therapeutics Secures $10 Million In Funding To Develop Personalized Therapies For Autoimmune Diseases | IM Therapeutics, a clinical-stage company developing personalized therapies for autoimmune diseases, announced it raised $10 million in Series A funding IM Therapeutics — a clinical-stage company that is developing personalized therapies fo... |
| 10.10.2019 | Daily funding roundup - October 9th, 2019 | Augmenta raised $2.5M; Doorstead landed $3.3M; Middesk picks up $4M; Papa closed $10M Augmenta: Augmenta is a precision agriculture company. Augmenta raised $2.5 million in seed funding co-led by Hardware Club and Marathon Venture Capital o... |
| 09.10.2019 | IM Therapeutics Raises $10M in Series A | AURORA, CO, ImmunoMolecular Therapeutics has raised $10 million in Series A financing. >> Click here for more funding data on IM Therapeutics >> To export IM Therapeutics funding data to PDF and Excel, click here ImmunoMo... |
| 09.10.2019 | IM Therapeutics Closes $10 Million Financing | AURORA, Colo. & BOSTON--(BUSINESS WIRE)--ImmunoMolecular Therapeutics, a clinical stage company developing personalized therapies for autoimmune disease, today announced that it has raised $10 million in Series A financing to advance it... |
| 09.10.2019 | ImmunoMolecular Therapeutics Raises $10M in Series A Funding | ImmunoMolecular Therapeutics, a Woburn, MA- and Aurora, Colo.-based clinical stage company developing personalized therapies for autoimmune disease, raised $10m in Series A financing. The round was co-led by the JDRF T1D Fund and Morningsid... |